OMA Guidelines Bundle

Obesity Pharmacotherapy - Obesity Algorithm 2024

Obesity Medicine Association OMA GUIDELINES App Bundle brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1349812

Contents of this Issue

Navigation

Page 32 of 33

33 OTC Anti-obesity Therapy Mechanism of Action Effects Side Effects Orlistat Intestinal lipase inhibitor that impairs intestinal fat absorption. Mild weight reduction Loose, oily stools. Possible deficiency in fat soluble vitamins, liver toxicity, and kidney stones. Weight Loss Therapies with Mandated Disclaimer by the FDA Intervention Proposed Mechanism of Action Effects Warnings HCG Marketed as reducing appetite and preserving muscle mass during administration of very low calorie diet. Meta-analyses do not support clinically significant weight loss. Since 1976, the FDA has mandated a disclaimer for those who administer HCG. a In 2016, the American Medical Association passed policy that "The use of HCG for weight loss is inappropriate." a 1976 FDA disclaimer for HCG: "ere is no substantial evidence that HCG increases weight loss beyond that resulting om caloric restriction, that it causes a more attractive or normal distribution of fat, or that it decreases the hunger and discomfort associated with calorie restrictive diets."

Articles in this issue

Archives of this issue

view archives of OMA Guidelines Bundle - Obesity Pharmacotherapy - Obesity Algorithm 2024